Member Info for Ralphiebabe

Majority of the team attending/presenting today, hope this the make not the break with the tool for prostrate cancer regime they've developed.

Noticed on new site a case study of CCS1477 ( a first-in-class small molecule to treat prostate and other cancers) by Cellcentrics of which Clinical protocol approved by regulatory agency.
https://www.physiomics.co.uk/wp-content/uploads/2019/03/CC-case-study.pdf

Cellcentrics also based at Magdalen Centre( same as Physiomics).
https://www.cellcentric.com/

For the presentation of:-
677 / 10 - A precision dosing application for prostate cancer chemotherapy.
They’re there to get some serious backer for this project, or it’s one big jolly as just about all staff attending!
Presenter/Authors,
Claire Villettte, Hitesh Mistry, Fernando G. Ortega, David Orrell, Frances A. Brightman, Jim Millen, Christophe Chassagnole. Physiomics plc, Oxford, United Kingdom.

680 / 13 - Predicting the effect of radiotherapy on tumor growth inhibition and time to progression in head and neck cancer
https://www.abstractsonline.com/pp8/#!/6812/presentation/1723

https://www.abstractsonline.com/pp8/#!/6812/presentation/1720

Pyc doing Abstract on 31st, looks like all presenting, hope they are successful with this.

We have developed a precision dosing app for Docetaxel in prostate cancer which requires a single weekly classical blood test in the first chemotherapy cycle. This app has the potential to significantly improve patient outcome at low cost without disrupting current clinical practice.

For a while there has been a constant flux of sells, me thinks those days are over now, without these should see so picking up also should be news out before aacr meeting end of month.

As mentioned in results yesterday, PYC attending AACR 2019 in Atlanta March 29 to April 3rd.
Had a look, unable to find any abstracts or presentations mentioned for PYC, did find they have an exhibition booth though.

https://aacr19.mapyourshow.com/7_0/exhview/index.cfm?selectedBooth=1851&CFID=43331354&CFTOKEN=49bb3877f907d6a8-CD01E8BF-9A5E-9271-26F5A2A8C053D9AE

Not putting a damper on expectations, it could well be that we may not hear anything. In the past at different periods of time PYC have announced collaborations with 3 different companies, with each one we never heard what had happened as nothing materialised with the collaborations. I know we are in a different situation here with Merck Kgaa. Also with Jim on board he may well like to keep us up to date, we'll just have to see what happens in next week or so. Have been with PYC for years and years so would like some positive news. GLA.

Jim at C2 booth. He doesn't look very inviting to potential customers. https://www.google.co.uk/url?sa=t&source=web&rct=j&url=https://twitter.com/physiomics%3Flang%3Den&ved=2ahUKEwjpxZiQ0tTeAhVK3KQKHfjAC3oQFjAAegQIBhAB&usg=AOvVaw2gdiLq4CWBOPaWmywRj7Te&cshid=1542224789134

Definite RNS on 20th. From AGM "All resolutions have been passed".

Physiomics booth is at C2, with competitors next to it booth C3 ProQinase GmbH ( a German cancer drug discovery platform).

https://www.ecco-org.eu/Events/ENA2018/Exhibition-and-Sponsorship/Floorplan#floorplanoverviewform

Has been updated to include latest recruit Dr Claire Villette profile. https://www.physiomics-plc.com/about/team/ Noticed number of buys this morning have sold up now.

https://www.proactiveinvestors.co.uk/companies/stocktube/10799/physiomics-reports-record-year-of-income-with-significant-contract-wins-10799.html

https://www.google.co.uk/url?sa=t&source=web&rct=j&url=https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-pyc/physiomics-shares/news/does-physiomics-plcs-lonpyc-ceo-pay-reflect-performance/amp/&ved=2ahUKEwiwrvbFoq7eAhUIIMAKHY7bCc4QFjADegQICRAB&usg=AOvVaw0d4DS3_tHpDGkSdYXrLuzH&ampcf=1 In 2016 Jim Millen was appointed CEO of Physiomics Plc (LON:PYC). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid

Have gone through program, doesn't look like Physiomics have any Abstracts or Poster Sessions.

They do have an exhibition booth at C2 ( 24 exhibits total).

https://www.ecco-org.eu/Events/ENA2018/Exhibition-and-Sponsorship/Floorplan#floorplanoverviewform

Expect RNS for following

Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for
Research and Treatment of Cancer (“EORTC”) acts as a hub for a network of over 930 institutions in 30 countries focused on translational and clinical cancer research.

Physiomics will host a stand for the full duration of the event, bringing it into contact with representatives of key academic and commercial organisations involved in the research and development of new cancer diagnostics and therapeutics.

https://www.physiomics-plc.com/physiomics-to-host-stand-at-eortc-dublin/

Have been doing some research on latest recruit, I'm wondering what she will be bringing to Physiomics as her background has not included oncology bio simulation. Not sure if company is branching off into a new area, or her background will bring something new to their Oncology program? Only time will tell, as Dr Jim Millen mentioned in latest video, she started full time in September.

Her latest update on Researchgate is "Rate and age-dependent damage elasticity formulation for efficient hip fracture simulation"

https://www.researchgate.net/publication/327539732_Rate_and_age-dependent_damage_elasticity_formulation_for_efficient_hip_fracture_simulations

and

HETEROGENEOUS DESIGN OPTIMISATION OF TISSUE ENGINEERING SCAFFOLDS:IN-VITRO ASSESSMENT OF A DIGITAL DESIGN FRAMEWORK.

http://cmbbe2018.tecnico.ulisboa.pt/pen_cmbbe2018/pdf/WEB_ABSTRACTS/Abstracts_CMBBE2018_129.pdf

Would love this to climb lot higher than what it is, but there's been about 1.25 million buys since Tuesday and there's not been much of a rise.

Utah, depends on any RNS being issued, if we break over 100 day moving average and sustain this, minimum it should drop then be low 4's.